Please ensure Javascript is enabled for purposes of website accessibility

Here's Why OPKO Health Shares Are Crashing 26.2% Today

By Todd Campbell - Mar 10, 2020 at 12:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Short-sellers are taking aim.

What happened

After short-seller Hindenburg Research posted a series of tweets questioning the future of OPKO Health (OPK 0.78%), its shares were down 26.2% at 12:30 p.m. EDT on Tuesday.

So what

OPKO Health's BioReference Labs is one of the largest patient testing laboratories in the United States. On March 5, it announced plans to roll out a test for the COVID-19 coronavirus, which sent OPKO's shares soaring. The rapid run-up in its shares prompted Hindenburg Research, a short-seller that's been bearish on OPKO Health since 2018, to reassert its belief that it will trade significantly lower, not higher.

A man listens through a wall using a plastic cup.

Image source: Getty Images.

Specifically, Hindenburg alleges that OPKO Health's COVID-19 testing news is a pump-and-dump scheme designed to boost shares and potentially force short-sellers to cover. As of Feb. 14, 23.03% of shares available for trading, or the share float, were held short.

Hindenburg also suggests OPKO Health could use the recent rally in its shares to announce a stock offering to bolster its balance sheet, which has been hamstrung by ongoing operating losses.

As evidence, the short-seller points out that OPKO Health's founder, Phillip Frost, its biggest shareholder, has been the subject of investigations into similar stock schemes. Hindenburg also cites OPKO's $82 million cash balance as its reason for anticipating a dilutive stock offering.

As a refresher, Frost is a well-known biotech entrepreneur. His resume includes transforming Key Pharmaceuticals into a major asthma treatment player that was acquired for nearly $800 million by Schering-Plough in 1986; founding IVAX, a major generic drug maker that was acquired by Teva Pharmaceutical (TEVA 1.53%) for roughly $7.5 billion in 2006, and serving as Teva's chairman from 2010 to 2014. Currently, he is OPKO's chairman and CEO.

The Securities and Exchange Commission filed a suit in September 2018, alleging Frost engaged in pump-and-dump schemes in microcap stocks. Frost settled with the SEC in December 2018, agreeing to pay a $5.5 million penalty without admitting wrongdoing.

Now what

There's no question that OPKO Health is burning through cash. In 2019, the healthcare company reported a $315 million net loss on revenue of $224 million. As a result, OPKO's cash balance slipped to $85.5 million from $96.5 million exiting 2018, despite raising $81.3 million via an underwritten public stock offering in Q4.

Nevertheless, BioReference Labs is a leading provider of lab services. And its footprint, including relationships with healthcare providers in key markets, including New York, California, and Florida, could mean it generates significant test volume from COVID-19 screening. In South Korea, hundreds of thousands of people have been tested, but U.S. screening is only now beginning to ramp up. Currently, estimates are that testing capacity is a little shy of 8,000 per day. Arguably, that's insufficient, suggesting there's room for BioReference Labs to win patient share.

The bulk of testing is likely to be done by larger competitors, including LabCorp (LH 1.71%), which already has a test available. But BioReference Labs test could be available next week, and since that business unit accounts for 80% of OPKO Health's revenue, investors might want to avoid shorting shares.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

OPKO Health, Inc. Stock Quote
OPKO Health, Inc.
OPK
$2.59 (0.78%) $0.02
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$7.95 (1.53%) $0.12
Laboratory Corporation of America Holdings Stock Quote
Laboratory Corporation of America Holdings
LH
$240.00 (1.71%) $4.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.